Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis A | 2 | 2020 | 140 | 1.45 | Why? |
| Sexual and Gender Minorities | 2 | 2020 | 1019 | 0.82 | Why? |
| Antiprotozoal Agents | 1 | 2019 | 83 | 0.74 | Why? |
| Sweet Syndrome | 1 | 2019 | 54 | 0.74 | Why? |
| Toxoplasmosis | 1 | 2019 | 59 | 0.74 | Why? |
| Hepatitis B Vaccines | 2 | 2018 | 245 | 0.74 | Why? |
| Hepatitis B | 4 | 2018 | 888 | 0.70 | Why? |
| Transgender Persons | 2 | 2020 | 322 | 0.66 | Why? |
| Daptomycin | 1 | 2017 | 64 | 0.64 | Why? |
| Neurocognitive Disorders | 1 | 2018 | 99 | 0.64 | Why? |
| Saccharomycetales | 1 | 2017 | 118 | 0.63 | Why? |
| Myelodysplastic Syndromes | 1 | 2019 | 261 | 0.62 | Why? |
| Indicators and Reagents | 1 | 2017 | 183 | 0.61 | Why? |
| HIV Envelope Protein gp120 | 1 | 2018 | 267 | 0.59 | Why? |
| Dysbiosis | 1 | 2021 | 685 | 0.58 | Why? |
| Prothrombin Time | 1 | 2017 | 434 | 0.57 | Why? |
| Immunodominant Epitopes | 1 | 2019 | 813 | 0.54 | Why? |
| Catheter-Related Infections | 1 | 2017 | 381 | 0.49 | Why? |
| Warfarin | 1 | 2017 | 402 | 0.48 | Why? |
| False Positive Reactions | 1 | 2017 | 1338 | 0.45 | Why? |
| Microbiota | 1 | 2021 | 1240 | 0.43 | Why? |
| HIV Infections | 4 | 2020 | 11620 | 0.42 | Why? |
| Mycoses | 1 | 2017 | 589 | 0.41 | Why? |
| Hepatitis B virus | 4 | 2018 | 882 | 0.40 | Why? |
| Tokyo | 2 | 2020 | 645 | 0.35 | Why? |
| Epitopes, T-Lymphocyte | 1 | 2019 | 2262 | 0.34 | Why? |
| Bacteremia | 1 | 2017 | 1372 | 0.30 | Why? |
| Lamivudine | 2 | 2020 | 210 | 0.26 | Why? |
| HIV | 2 | 2020 | 1116 | 0.25 | Why? |
| Guanine | 2 | 2018 | 146 | 0.25 | Why? |
| HIV-1 | 1 | 2018 | 3365 | 0.24 | Why? |
| Machine Learning | 1 | 2019 | 4395 | 0.24 | Why? |
| Adenine | 2 | 2020 | 463 | 0.24 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.23 | Why? |
| Japan | 3 | 2020 | 6653 | 0.23 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.22 | Why? |
| Homosexuality, Male | 2 | 2020 | 1158 | 0.22 | Why? |
| Dideoxynucleosides | 1 | 2020 | 92 | 0.21 | Why? |
| Drug Resistance, Viral | 1 | 2007 | 1083 | 0.21 | Why? |
| HLA-DRB1 Chains | 1 | 2021 | 196 | 0.20 | Why? |
| Emtricitabine | 1 | 2020 | 202 | 0.20 | Why? |
| Major Histocompatibility Complex | 1 | 2019 | 70 | 0.19 | Why? |
| Therapeutic Irrigation | 1 | 2020 | 167 | 0.19 | Why? |
| Anti-Bacterial Agents | 3 | 2019 | 10083 | 0.19 | Why? |
| Heterocyclic Compounds, 4 or More Rings | 1 | 2020 | 139 | 0.19 | Why? |
| Insulin Receptor Substrate Proteins | 1 | 2018 | 13 | 0.19 | Why? |
| Oxazines | 1 | 2020 | 279 | 0.18 | Why? |
| Liver Neoplasms | 3 | 2018 | 1666 | 0.18 | Why? |
| Carcinoma, Hepatocellular | 2 | 2018 | 1222 | 0.18 | Why? |
| beta Catenin | 1 | 2018 | 78 | 0.18 | Why? |
| Mucorales | 1 | 2018 | 92 | 0.17 | Why? |
| Cytokines | 2 | 2021 | 15010 | 0.17 | Why? |
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 275 | 0.17 | Why? |
| Piperazines | 1 | 2020 | 445 | 0.17 | Why? |
| Tenofovir | 1 | 2020 | 449 | 0.16 | Why? |
| Hepatitis B Antibodies | 1 | 2017 | 142 | 0.15 | Why? |
| Echinocandins | 1 | 2017 | 139 | 0.15 | Why? |
| Antigen Presentation | 1 | 2019 | 524 | 0.15 | Why? |
| Hepatitis C | 1 | 2007 | 1514 | 0.15 | Why? |
| Mouthwashes | 1 | 2020 | 432 | 0.15 | Why? |
| Helicobacter Infections | 1 | 2018 | 216 | 0.15 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.15 | Why? |
| Helicobacter pylori | 1 | 2018 | 262 | 0.15 | Why? |
| Thermodynamics | 1 | 2019 | 873 | 0.14 | Why? |
| Pyridones | 1 | 2020 | 738 | 0.14 | Why? |
| Lipopeptides | 1 | 2017 | 229 | 0.14 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.13 | Why? |
| Endocarditis, Bacterial | 1 | 2019 | 344 | 0.13 | Why? |
| Toll-Like Receptors | 1 | 2017 | 365 | 0.13 | Why? |
| Seroconversion | 2 | 2020 | 2515 | 0.13 | Why? |
| Antigens, Viral | 2 | 2021 | 6298 | 0.13 | Why? |
| Receptors, Antigen, T-Cell | 1 | 2019 | 760 | 0.13 | Why? |
| Staphylococcus aureus | 1 | 2019 | 844 | 0.12 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 2309 | 0.12 | Why? |
| DNA, Viral | 1 | 2002 | 2521 | 0.12 | Why? |
| Datasets as Topic | 1 | 2019 | 1404 | 0.12 | Why? |
| Non-alcoholic Fatty Liver Disease | 2 | 2018 | 907 | 0.12 | Why? |
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1014 | 0.11 | Why? |
| Databases, Genetic | 1 | 2018 | 1127 | 0.11 | Why? |
| Microbial Sensitivity Tests | 2 | 2019 | 2886 | 0.11 | Why? |
| Hepatitis B, Chronic | 1 | 2018 | 616 | 0.11 | Why? |
| Heart-Assist Devices | 1 | 2019 | 812 | 0.11 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Heart Ventricles | 1 | 2019 | 1139 | 0.10 | Why? |
| Humans | 26 | 2021 | 930598 | 0.10 | Why? |
| Staphylococcal Infections | 1 | 2019 | 1099 | 0.10 | Why? |
| Cluster Analysis | 1 | 2018 | 3001 | 0.10 | Why? |
| Convalescence | 1 | 2020 | 2829 | 0.10 | Why? |
| Mucormycosis | 1 | 2018 | 832 | 0.10 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.09 | Why? |
| Blood Donors | 1 | 2002 | 2956 | 0.09 | Why? |
| Hepatitis B Surface Antigens | 2 | 2017 | 305 | 0.09 | Why? |
| Gastrointestinal Microbiome | 1 | 2021 | 1961 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.09 | Why? |
| Anti-HIV Agents | 1 | 2020 | 2209 | 0.08 | Why? |
| Feces | 1 | 2021 | 4235 | 0.08 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.08 | Why? |
| Adaptive Immunity | 1 | 2019 | 2585 | 0.08 | Why? |
| Organophosphonates | 1 | 2007 | 85 | 0.08 | Why? |
| Point-of-Care Systems | 1 | 2020 | 2955 | 0.08 | Why? |
| Male | 14 | 2020 | 367725 | 0.08 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.08 | Why? |
| Antifungal Agents | 1 | 2017 | 1828 | 0.08 | Why? |
| Specimen Handling | 2 | 2020 | 6190 | 0.08 | Why? |
| Liver | 2 | 2018 | 4007 | 0.07 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.07 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.07 | Why? |
| MicroRNAs | 1 | 2018 | 1787 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.07 | Why? |
| Hospitals, University | 1 | 2017 | 4173 | 0.07 | Why? |
| Interferons | 1 | 2017 | 2885 | 0.07 | Why? |
| Prospective Studies | 3 | 2018 | 43301 | 0.07 | Why? |
| Computer Simulation | 1 | 2019 | 4982 | 0.07 | Why? |
| Hepacivirus | 2 | 2018 | 1509 | 0.07 | Why? |
| False Negative Reactions | 2 | 2020 | 1785 | 0.07 | Why? |
| Computational Biology | 1 | 2019 | 4514 | 0.06 | Why? |
| Bacterial Infections | 1 | 2017 | 2229 | 0.06 | Why? |
| Hepatitis B Core Antigens | 1 | 2002 | 76 | 0.06 | Why? |
| alpha-Fetoproteins | 1 | 2003 | 72 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.06 | Why? |
| Artificial Intelligence | 1 | 2018 | 3543 | 0.06 | Why? |
| Prothrombin | 1 | 2003 | 149 | 0.06 | Why? |
| Antiviral Agents | 3 | 2020 | 41703 | 0.06 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.06 | Why? |
| X-Ray Microtomography | 1 | 2021 | 115 | 0.06 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.06 | Why? |
| Female | 9 | 2020 | 380317 | 0.05 | Why? |
| Biomarkers | 2 | 2021 | 23361 | 0.05 | Why? |
| Immunoglobulin Class Switching | 1 | 2021 | 133 | 0.05 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.05 | Why? |
| RNA, Ribosomal, 23S | 1 | 2019 | 25 | 0.05 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.05 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.05 | Why? |
| Viral Nonstructural Proteins | 1 | 2017 | 4810 | 0.05 | Why? |
| Protein Precursors | 1 | 2003 | 425 | 0.05 | Why? |
| Adult | 7 | 2020 | 244371 | 0.05 | Why? |
| Cyclin-Dependent Kinases | 1 | 2018 | 124 | 0.05 | Why? |
| Linezolid | 1 | 2019 | 160 | 0.04 | Why? |
| Tumor Suppressor Proteins | 1 | 2018 | 165 | 0.04 | Why? |
| Aged | 6 | 2020 | 215776 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2018 | 238 | 0.04 | Why? |
| Hep G2 Cells | 1 | 2018 | 391 | 0.04 | Why? |
| Stomach Neoplasms | 1 | 2003 | 477 | 0.04 | Why? |
| Genotype | 2 | 2021 | 4697 | 0.04 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Blood Banks | 1 | 2002 | 535 | 0.04 | Why? |
| Carcinogenesis | 1 | 2018 | 236 | 0.04 | Why? |
| Gene Frequency | 1 | 2021 | 1210 | 0.04 | Why? |
| Antibody Affinity | 1 | 2021 | 1078 | 0.04 | Why? |
| Mesocricetus | 1 | 2021 | 1847 | 0.04 | Why? |
| Adenocarcinoma | 1 | 2003 | 651 | 0.04 | Why? |
| Vaccination | 2 | 2018 | 19050 | 0.04 | Why? |
| Alleles | 1 | 2021 | 1557 | 0.04 | Why? |
| Carrier Proteins | 1 | 2018 | 513 | 0.04 | Why? |
| DNA Primers | 1 | 2018 | 1170 | 0.03 | Why? |
| Cricetinae | 1 | 2021 | 3344 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.03 | Why? |
| Kinetics | 1 | 2021 | 3238 | 0.03 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 711 | 0.03 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.03 | Why? |
| Opportunistic Infections | 1 | 2018 | 602 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2017 | 2739 | 0.02 | Why? |
| Mice | 2 | 2021 | 21357 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2018 | 3608 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Insulin | 1 | 2018 | 1316 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Fatal Outcome | 1 | 2018 | 3438 | 0.02 | Why? |
| Protein Domains | 1 | 2021 | 6563 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| HEK293 Cells | 1 | 2021 | 8394 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Gene Expression Profiling | 1 | 2018 | 3788 | 0.02 | Why? |
| Genetic Predisposition to Disease | 1 | 2021 | 4027 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Immunoassay | 1 | 2020 | 4485 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Blood Glucose | 1 | 2018 | 3642 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Polymerase Chain Reaction | 1 | 2018 | 6740 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Pandemics | 2 | 2020 | 389249 | 0.01 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 7868 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2020 | 11367 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Animals | 2 | 2021 | 78931 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Retrospective Studies | 2 | 2020 | 105322 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.01 | Why? |
| Immunohistochemistry | 1 | 2003 | 2275 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Risk Factors | 1 | 2018 | 71621 | 0.01 | Why? |
| Adolescent | 1 | 2017 | 86841 | 0.00 | Why? |
| Young Adult | 1 | 2017 | 93724 | 0.00 | Why? |
Yotsuyanagi's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(204)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(162)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_